Phase Ib Study of Crizotinib plus Pembrolizumab in Patients with Previously Untreated Advanced Non‐Small Cell Lung Cancer with ALK Translocation

LESSONS LEARNED: This study evaluating first‐line crizotinib plus pembrolizumab in patients with anaplastic lymphoma kinase (ALK)–positive advanced non‐small cell lung cancer (NSCLC) was terminated early because increased availability of second‐generation ALK inhibitors resulted in difficulty identi...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Oncologist
Asıl Yazarlar: Patel, Sandip Pravin, Pakkala, Suchita, Pennell, Nathan A., Reckamp, Karen L., Lanzalone, Silvana, Polli, Anna, Tarazi, Jamal, Robert‐Vizcarrondo, Francisco
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley & Sons, Inc. 2020
Konular:
Clinical Trial Results
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7356710/
https://ncbi.nlm.nih.gov/pubmed/32048771
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2020-0034
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller